Skip to content

True precision medicine through single cell science

Precise diagnosis and targeted treatments improve patient outcomes. Scailyte’s pioneering technology integrates multimodal single cell and clinical data to identify novel disease signatures.

Supported by

Our pillars

High-quality biomedical data sets

Targeted, trustworthy and sensitive algorithms

.

Bold industrialization and adoption

On a mission to discover and develop biomarkers for precision medicine using single cell data and Artificial Intelligence.

Scailyte is an AI enabled company transforming precision medicine for the medical R&D community. Scailyte is a multi-disciplinary diverse team, science and solution partner.

ScaiVisionTM, our proprietary and best-in-class biomarker discovery platform, can expose precise novel molecular signatures with deep cellular insights.

From discovery to next generation clinical applications

Study Design

Defining hypothesis

Wet/Dry lab setup and experimental design

Data analysis workflow

Data Acquisition

Identification and optimization of suitable single-cell method(s)

 

Sample preparation and processing

Biomedical insights

Data processing, analysis and interpretation using our AI-based technology
Identification of biomarkers and cell-identity signatures

Establishing a precision diagnostics portfolio

Single-cell data allows for unprecedented insight into health and disease, opening new avenues for diagnostics and therapeutics of complex diseases areas like oncology and women’s health.

+ 6 new indications to be initiated in 2020/2021

Accelerating innovation through partnerships

Making groundbreaking discoveries and bringing innovation into clinical practice requires strong collaborations and joint-ventures.

Scailyte unlocks novel disease insights for medical researchers, accelerating late stage medical R&D and increasing the chance of successful drug development. We are looking for partners to step up and passionately pursue our science to address unmet patient needs.

We are multi-disciplinary team with tech, science and business expertise.

Our investors

Recent News

ScaiVision® performs best-in-class at sample class prediction!

ScaiVision® v1.0.0 was released internally and benchmarked in a massive experiment, outperforming a

Read more

Recent News

Scailyte participates @ swissnex san francisco DEMO DAY!

Striving to internationalize and network, Scailyte participates and pitches at the swissnex Demo Day

Read more

Recent News

Scailyte Q3 2020 Update

Q3 2020 update on Scailyte's progress towards its mission to save millions of lives.

Read more

Recent News

ETH Industry E-Week 2020 features Scailyte with the headline: Using Artificial Intelligence to unlock the clinical potential of single-cell data.

As ETH- Spin-off Scailyte attends the 2020 Industry eWeek giving updates on the disease area focus,

Read more

Recent News

Interview with Scailyte’s CEO Peter Nestorov

In the interview done by Venturelab, Peter talks about the challenges of an entrepreneur. As the CEO

Read more

Recent News

Interview with Scailyte Founder Prof. Dr. Manfred Claassen

In an interview with Investiere our founder and scientific advisor Prof. Dr. Manfred Claassen descri

Read more

Recent News

Scailyte: simplifying difficult diagnoses

Making a diagnosis can be a tricky endeavour. For instance, diagnosing skin T-cell lymphoma, a rare

Read more

Recent News

01 /04

ScaiVision® performs best-in-class at sample class prediction!

ScaiVision® v1.0.0 was released internally and benchmarked in a massive experiment, outperforming a

Read more

Scailyte participates @ swissnex san francisco DEMO DAY!

Striving to internationalize and network, Scailyte participates and pitches at the swissnex Demo Day

Read more

Recent News

02 /04

Scailyte Q3 2020 Update

Q3 2020 update on Scailyte's progress towards its mission to save millions of lives.

Read more

ETH Industry E-Week 2020 features Scailyte with the headline: Using Artificial Intelligence to unlock the clinical potential of single-cell data.

As ETH- Spin-off Scailyte attends the 2020 Industry eWeek giving updates on the disease area focus,

Read more

Recent News

03 /04

Interview with Scailyte’s CEO Peter Nestorov

In the interview done by Venturelab, Peter talks about the challenges of an entrepreneur. As the CEO

Read more

Recent News

04 /04

Interview with Scailyte Founder Prof. Dr. Manfred Claassen

In an interview with Investiere our founder and scientific advisor Prof. Dr. Manfred Claassen descri

Read more

Scailyte: simplifying difficult diagnoses

Making a diagnosis can be a tricky endeavour. For instance, diagnosing skin T-cell lymphoma, a rare

Read more

Recent News